Sort   by:  
 Page size 
UnknownChimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job.
Not available
S-EPMC8154758 | biostudies-literature
UnknownRIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Not available
S-EPMC7214254 | biostudies-literature
UnknownA modular and controllable T cell therapy platform for acute myeloid leukemia.
Not available
S-EPMC7789085 | biostudies-literature
UnknownAdvances in cancer immunotherapy 2019 - latest trends.
Not available
S-EPMC6585101 | biostudies-literature
UnknownChimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy.
Not available
S-EPMC6558337 | biostudies-literature
UnknownCooperative CAR targeting to selectively eliminate AML and minimize escape.
Not available
S-EPMC11006543 | biostudies-literature
UnknownT-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
Not available
S-EPMC8257483 | biostudies-literature
UnknownNovel immunotherapies in the treatment of AML: is there hope?
Not available
S-EPMC10727092 | biostudies-literature
UnknownImmune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy.
Not available
S-EPMC8078464 | biostudies-literature
UnknownBlood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens.
Not available
S-EPMC8614222 | biostudies-literature
Sort   by:  
 Page size